Health Condition 1: L088- Other specified local infections of the skin and subcutaneous tissue
Conditions
Interventions
Intervention1: NIL: NIL
Sponsors
IADVL
Eligibility
Inclusion criteria
Inclusion criteria: All newly diagnosed treatment-naive cases of all age groups and both sex with a clinical diagnosis of leprosy according to Indian Classification, who on slit skin smear or Biopsy display a bacillary index 0-6. RFT cases of Hansen s with signs of Relapse, Reinfection, or recurrent ENL leprosy with a bacillary index 0-6. Patients willing to participate and provide informed consent in the study. Severely ill patients with leprosy
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Detection of Antimicrobial Resistance (AMR): Identification of drug resistance mutations in Mycobacterium leprae using SNP (Single Nucleotide Polymorphism) analysis. Assessment of resistance to key anti-leprosy drugs (e.g., dapsone, rifampicin, and ofloxacin) in leprosy patientsTimepoint: 2 year | — |
Secondary
| Measure | Time frame |
|---|---|
| Viability of M. leprae Post-Treatment: Evaluation of the persistence of viable M. leprae in patients after completion of Multidrug Therapy (MDT) using Molecular Viability Assay (MVA). Comparative Histopathological Study of Leprosy in Gujarat: Examination of the histopathological spectrum of leprosy cases to identify variations in clinical presentation, disease progression, and response to treatment.Timepoint: 2 year | — |
Countries
India
Contacts
Public ContactAnkit Hemantkumar Bharti
Dr. Ankit Bharti s dermatopathology research centre Pvt. Ltd.
Outcome results
None listed